Table 4. Viral load and CD4 counts at the beginning and the end of the study.
| VL_start | VL_end | ΔVL | P values a | |||||||
| Group | cp/ml ± SEM | cp/ml ± SEM | cp/ml ± SEM | Log_ΔVL | CD4_Start | CD4_Last | ΔCD4b | |||
| (No. of Patients) | Log(cp/ml) ±SEM | Log(cp/ml) ±SEM | Log(cp/ml) ±SEM | Log (cp/ml) ±SEM | cells/µl ±SEM | cells/µl ±SEM | cells/µl ±SEM | ΔVL | CD4 Start | ΔCD4 |
| [Range] | [Range] | [Range] | ||||||||
| Total (607) | 64,200±47,036 | 399±16,845 | 41,601±49,088 | |||||||
| 4.81±0.05 | 2.60±0.05 | 4.62±0.12 | 1.85±0.06 | 186±8.9 | 341±11.3 | 12±8.4 | ||||
| [25–19,000,000] | [25–9,000,000] | [−8.250,000±18,999,601] | [−1.79±5.06] | |||||||
| [1.40–7.28] | [1.40–6.95] | [−6.96±7.23] | ||||||||
| B (139) | 42,000±39,941 | 199±66,632 | 36,601±73,6232 | 2.35±0.14 | 216±20.8 | 468±27.2 | 175±22.9 | B vs. C | ||
| 4.63±0.12 | 2.30±0.09 | 4.63±0.24 | 0.2 | 0.5 | <0.0001 | |||||
| C (391) | 55,700±63,584 | 399±11,001 | 37,975±63458 | 2.00±0.07 | 178±10.8 | 306±12.7 | 98±8.6 | C vs. non-BC | ||
| 4.76±0.06 | 2.60±0.05 | 5.00±0.16 | 0.2 | 0.8 | <0.0001 | |||||
| Non-BC (77) | 95,000±161,780 | 399±12,835 | 86,383±162,232 | 2.60±0.12 | 196±21.8 | 386±31.7 | 203±26.5 | B vs. non-BC | ||
| 4.98±0.15 | 2.60±0.12 | 5.00±0.29 | 0.1 | 0.7 | 0.5 | |||||
| M (365 | 70,000±50,705 | 399±27,787 | 49,240±55,734 | 2.08±0.08 | 165±11.5 | 313±14.1 | 122±10.0 | |||
| 4.85±0.07 | 2.60±0.06 | 4.70±0.16 | M vs. F | |||||||
| F (242) | 45,300±89,546 | 399±6,377 | 32,815±89,426 | 1.60±0.09 | 220±13.9 | 372±18.4 | 121±14.7 | 0.6 | 0.02 | 0.5 |
| 4.65±0.08 | 2.60±0.07 | 5.00±0.19 | ||||||||
| Ongoing (429) | 58,300±63,594 | 399±7,930 | 43,801±63,190 | 2.60±0.05 | 196±11.5 | 362±13.6 | 154±10.5 | |||
| 4.77±0.06 | 2.60±0.05 | 4.76±0.06 | 1st PI vs. 2nd _PI | |||||||
| Stopped (177) | 67400±45,934 | 399±54,874 | 36,700±67,961 | 1.54±0.13 | 176±12.4 | 250±19.0 | 61±12.8 | <0.0001 | <0.0001 | 0.005 |
| 4.83±0.10 | 2.60±0.11 | 4.57±0.26 | ||||||||
| 1st PI (300) | 80,400±79,259 | 399±10,389 | 74,801±74,453 | 2.27±0.09 | 175±10.1 | 340±14.4 | 162±11.0 | |||
| 4.91±0.08 | 2.60±0.06 | 4.90±0.16 | 1st PI vs. 2nd _PI | |||||||
| 2nd _PI (307) | 47,300±56,585 | 399±31,807 | 27,651±63,581 | 1.48±0.08 | 196±14.3 | 346±17.3 | 92±12.6 | <0.0001 | <0.0001 | 0.005 |
| 4.67±0.07 | 2.60±0.07 | 4.44±0.18 | ||||||||
| MSM (75) | 120,000±54,809 | 140±120,534 | 87,975±126,564 | 2.60±0.20 | 178±25.9 | 388±34.5 | 186±25.5 | |||
| 5.08±0.16 | 2.15±0.14 | 4.94±0.35 | MSM vs. C_M | |||||||
| C_M (192) | 71,700±69,286 | 399±21,087 | 56,251±68,457 | 1.92±0.11 | 145±16.0 | 269±18.2 | 84±10.3 | 0.1 | 0.003 | 0.0008 |
| 4.86±0.09 | 2.60±0.08 | 4.72±0.24 | ||||||||
Patients were grouped as in Table 3. The median of the individual CD4 changes, ΔCD4, was calculated for each group (rather than the difference between the medians of CD4 counts). Selected p-values between relevant groups are shown. Significant differences between groups in other parameters were not found.
Abbreviations: 1st_PI – patients receiving LPV/r as first PI; 2nd _PI – patients receiving LPV/r as second or higher-order PI; B – patients with HIV subtype B; C – patients with HIV subtype C; C_M – male patients with subtype C; F –female; F-UP – follow up, time from diagnosis to start of the study, in years; M– male; MSM – men who have sex with Men; non-BC- patients with HIV subtype other than subtype B or C; PI – protease inhibitor; VL – viral load; <LDL - below detection level.
p values were calculated between groups in the box. The C or non-BC groups were compared to the B group.
the median values of the individual ΔCD4 values of patients.